NRX Pharmaceuticals Inc（NRXP）财务数据NRXPNRX Pharmaceuticals Inc

Evaluating the bottom line, NRX Pharmaceuticals Inc maintains a gross margin of 32.70%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -590.46%, while the net margin is -1500.45%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively NRXP converts its operational activities into shareholder value.

In the context of the broader market, NRXP competes directly with industry leaders such as PYPD and NERV. With a market capitalization of $112.14M, it holds a leading position in the sector. When comparing efficiency, NRXP's gross margin of 32.70% stands against PYPD's N/A and NERV's N/A. Such benchmarking helps identify whether NRX Pharmaceuticals Inc is trading at a premium or discount relative to its financial performance.

The company reported a gross margin of 32.70% for Q2 2026, showing some profitability potential despite significant losses. Total revenue for Q2 2026 was $1,101,000, indicating growth from previous quarters, but the overall financial health remains precarious with a current ratio of 0.86.